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ABSTRACT 
In both daily practice and clinical trials, it remains difficult to reliably evaluate patients’ 
functioning in everyday life, over long periods of time, and using methods sensitive to 
relevant milestones. Examples include fluctuating events (e.g., response to medication), 
rare incidents (e.g., falls), and non-motor complications (e.g., orthostatic hypotension). 
The miniaturization, sophistication, proliferation, and accessibility of sensing 
technologies are now enabling the acquisition of data suitable to capture more and 
previously inaccessible phenomena in Parkinson disease (PD). However, a gap remains 
between the amount of information gathered using these technologies and the 
corresponding insights into disease complexity that should be gained to satisfy diagnostic 
and therapeutic needs. Challenges include the variety of non-compatible technology 
platforms, the feasibility of wide-scale and long-term deployment of sensor technology 
(in particular among vulnerable elderly patients), and the gap between the “big data” 
acquired with sensitive measurement technologies and their limited clinical application. 
Major opportunities could be realized if new technologies are developed as part of open-
source and/or open-hardware platforms enabling multi-channel data capture, sensitive to 
the broad range of motor and non-motor problems that characterize PD, and adaptable 
into self-adjusting, individualized treatment delivery systems. The International 
Parkinson and Movement Disorders Society Task Force on Technology is entrusted to 
convene engineers, clinical researchers, and patients to promote the development of 
integrated measurement and closed-loop therapeutic systems with high patient adherence 
that also serve to: 1) encourage the adoption of clinico-pathophysiologic phenotyping and 
early detection of critical disease milestones; 2) enhance tailoring of symptomatic 
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therapy; 3) improve subgroup targeting of patients for future testing of disease modifying 
treatments; and 4) identify objective biomarkers to improve longitudinal tracking of 
impairments in clinical care and research.  This article summarizes the work carried out 
by the Task Force toward identifying challenges and opportunities in the development of 
technologies with potential for improving the clinical management and quality of life of 
individuals with PD.  
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INTRODUCTION 
During the last decade, a multitude of technology-based objective measures of 
parkinsonian impairments have been developed, bringing with them the promise of 
substantially changing the diagnostic, monitoring and therapeutic landscape in Parkinson 
disease (PD). Sensors, mobile communications, cloud computing, advanced analytics, 
and the Internet of Things (wireless connectivity of all electronic devices),
1, 2
 are among 
the innovations that have the potential to transform healthcare and our approach to 
patients with chronic, complex and fluctuating disorders. With the abundance of new 
technologies, their growing power and versatility, and the smart algorithms upon which 
they increasingly rely, our field needs to ponder the basic questions of why we should 
even consider adding alternative measures, what clinical needs should be addressed, what 
instruments should be used, how to deploy new technologies with minimal burden, 
disruption and cost and maximal compliance, and whether they replace or complement 
existing resources. Unfortunately, technology developers appear to be operating in 
competing “islands of expertise” whose focus may be redundant, thus increasing the risk 
of duplicating rather than extending progress while potentially making their technologies 
incompatible with those of other developers. Also, not all technologies are primarily 
driven by burning questions from within the clinical field, sometimes creating technical 
solutions that – clever as they may be – remain in search of a clinical indication. 
 
In the absence of well-established and validated biomarkers for diagnosis or disease 
progression, PD remains a clinically defined disease. Today, clinical scales and 
traditional patient-reported outcomes continue to be the primary assessment tools or 
 12 
endpoints in both clinical care and research in PD. However, there is growing awareness 
that technology-based objective measures (TOMs) may improve the sensitivity, accuracy, 
reproducibility and feasibility of objectively capturing the full complexity and diversity 
of changes in motor and non-motor behaviors.
3-7
 Examples include the difficulty to 
reliably evaluate fluctuating events (e.g., the variable response to medication), to capture 
rare incidents (e.g., falls, or freezing of gait) or to assess behaviors that, by definition, 
take place over long periods of time outside the clinical examination room (e.g. physical 
activities in everyday life). The ability to remotely capture behavioral data and use it to 
optimize treatment strategies has the potential to finally “close the loop” and address 
critical knowledge gaps.
8
 Despite multiple ongoing projects by stakeholders in academia 
and industry, it remains challenging to determine what initiatives are ready to be scaled 
up, and what type of deployment would ensure the highest yield in the future.   
 
This review summarizes the deliberations of the International Parkinson and Movement 
Disorders Society Task Force on Technology.  As a first step, we centered on assessing 
the landscape of wearable devices and other technologies for individualized assessments, 
as well as the therapeutic and scientific uncertainties they stand to fill, rather than on 
assessing the clinimetric properties of any of the growing list of measurement 
technologies that have become available in the last 10 years. For the latter purpose, a 
number of reviews have been recently published.
9-11
 The Task Force is entrusted with 
bringing together experts from the device and biopharmaceutical industry, clinical 
researchers, engineers, and patients to brainstorm on needed developments to advance PD 
research and care. We aim at appraising the extent to which technology and data analysis 
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in general, and TOMs in particular, can bring robust granularity to the clinical complexity 
of PD in order to facilitate clinico-pathophysiologic phenotyping, the detection of 
prodromal symptoms, the improvement of diagnostic accuracy, progression monitoring, 
and to begin the process of integrating technology-based diagnostics and actionable 
pharmacological and non-pharmacological therapeutics for clinical applications.  
 
DEFINITIONS AND OBJECTIVES 
TOMs are the outcome of device-based instrumented clinical tests conducted by 
clinicians in standardized environments to objectively measure specific behaviors, or 
self-administered by patients to detect and monitor impairments in specific or overall 
function in everyday life. Initially, TOMs targeted motor phenomena, such as gait or 
balance, and were gathered in specialized movement laboratories.
12
 More recently, they 
have been extended to devices worn by the patient (i.e., wearable sensors and systems) in 
the clinic and –for remote monitoring– in the home or community settings (Figure 1).13-15 
The goal of wearable technologies is to maximize the “ecological” validity as well as the 
temporal and spatial resolution of capturing motor and non-motor phenomena that are 
naturally expected to change over time. As such, wearable technology may provide a 
more “realistic” portrayal of behaviors of interest in clinical and research settings.16 In 
addition, in the research arena, increasing the number of data points through greater 
temporal and spatial resolution of a targeted behavior is expected to reduce the sample 
size required to evaluate the effect of therapeutic interventions assuming the ratio of 
signal to noise can be maintained or improved.
17
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Important goals of TOMs are to provide objective parameters in the detection and 
monitoring of motor and non-motor functions, thereby enhancing the quality of treatment 
delivery and allowing for personalized care (Table 1). Currently available wearable 
technologies (inertial sensors, surface electromyography [EMG]) are – with variable 
success – capable of capturing the number and intensity of multiple activities, such as the 
frequency and amplitude of movements during the day and while asleep, the frequency 
with which tremor and dyskinesia appear and disappear during the day, and the 
fluctuations in the severity of gait and balance impairments.
18-22
 The use of consumer 
wearable technologies in medicine is becoming increasingly more common. For instance, 
in the field of sleep medicine, the use of actigraphy for sleep monitoring is already 
starting to supplant more traditional methods like polysomnography due to its validity, 
lower cost, and ability to evaluate individuals in their homes over a longer period of 
time.
23
 Advanced wearable technologies can also precisely monitor skin conductance, 
respiratory rate, blood pressure, oximetry and provide surface EMG, electrocardiography 
(ECG) and electroencephalography (EEG) tracings.
24-29
 Furthermore, the ability to collect 
TOMs using smart devices (mobile phones, tablets, and smart watches) provides 
additional opportunities to collect and analyze numerous clinically-relevant parameters 
(e.g., posture, balance, dexterity, voice and speech patterns, facial expression, eye 
tracking, medication and exercise compliance and adherence) and develop 
communication portals to improve patient engagement and self-management.  
 
Caveat emptor: Why measure at all? The often-implied assumption that the sole 
existence of a PD symptom justifies its measurement and that all PD-related phenomena 
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should be measured must be dispelled. A measure is justified if it enhances our 
understanding of a complex disease or aids in testing or delivering a therapy. The use of 
measurements to improve therapy is filled with rich examples from other branches of 
medicine (e.g., glucose monitoring for insulin pumps, cardiac defibrillators). It should be 
remembered that every qualitative clinical assessment is a form of measurement and that 
the use of quantitative measures carries potential for improving the decision-making 
process as to the need and dose of therapy. Implicit however is that what is being 
measured represents a therapeutic target and hence the measurement must be relevant to 
the treatment question (Table 1). 
 
The case for multi-domain, multi-sensor, integrated technology. PD is characterized by 
considerable inter- and intra-subject clinical variability in clinical symptoms. What 
matters most for one patient in the motor sphere may not be as important for another 
(e.g., tremor vs. freezing of gait vs. sleep disturbance) given the different levels of 
functional disability.
30
 Fluctuations in daily functioning in some patients may only 
include non-motor phenomena (e.g., fatigue or anxiety).
31
 Even if we were to accurately 
measure the most overt deficit, most patients display a repertoire of motor and non-motor 
endpoints that vary within and between days, with varying impact on their quality of 
life.
32
 Thus, a multi-domain, multi-sensor, smart technology is needed to determine the 
source of all relevant changes, identify individualized disease fingerprints, and develop 
truly personalized therapeutic approaches.  
 
CHALLENGES 
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The need for monitoring non-motor symptoms. The development of wearable systems to 
monitor individuals with PD has been focused heavily on motor aspects of the disease 
(e.g., tremor, bradykinesia, gait impairment, and dyskinesia)
33-35
 that are also, albeit with 
lower sensitivity and specificity, evaluated by clinical scales. Despite recent advances in 
the quantification of motor symptoms such as tremor, these endpoints often bear only 
modest quantitative agreement with measures of quality of life.
36, 37
 Indeed, patient 
priorities and sources of disability often arise from non-motor deficits (e.g., depression, 
anxiety, fatigue, orthostatic hypotension, sleep disturbance). Unfortunately, relatively few 
studies have thus far focused on capturing the fluctuations of these complex disease 
manifestations, marked by high variability within and between days.
38, 39
 The 
development of TOMs for non-motor endpoints has relied upon labor intensive or 
computerized, laboratory-based measurements (e.g., cognitive function, heart-rate 
variability, blood pressure changes, or sleep).
40, 41
 There is an urgent need for developing 
unobtrusive systems to monitor non-motor endpoints in the home and community 
settings. 
 
Limitations of sensors used to monitor motor symptoms. Biomechanical sensors such as 
accelerometers, gyroscopes, and magnetometers are well suited for the detection of 
tremor, bradykinesia, gait impairment, and motor complications, such as dyskinesia. 
However, data collected in the home and community settings using these sensors do not 
always provide sufficient information to achieve a reliable clinical assessment of motor 
symptoms. For instance, it is difficult to infer from the sensor data alone if slowness of 
movement (as detected using biomechanical sensors) can be used as a proxy of 
 17 
bradykinesia, or is the result of fatigue or other factors related to the context in which a 
motor task is performed (e.g., slow walking due to fear of falling). Also, the resolution of 
biomechanical sensors is quite restricted to the anatomical area on which they are 
applied, which may yield low quantitative agreement with the wider range of motor 
disability, quality of life, and other measurable patient-relevant endpoints.
36, 37
  
 
Discrepancy between clinical needs and research. Endpoints that may be ideally suited 
for a clinical study may not necessarily be relevant or applicable in clinical care. The 
relevance of specific TOMs to assessing the impact of parkinsonian symptoms on 
patients’ quality of life may be difficult to evaluate. For instance, fluctuations in motor 
symptoms and complications such as dyskinesia may have a complex quantitative 
relationship with measures of disability.
42
 In addition, the measurement target and 
timeline of data capture differ depending on the goals of a study. For example, an 
instrumented test that captures finger tapping over several hours may suffice to track the 
immediate response to a dopaminergic therapy. However, monitoring disease progression 
over time involves more complex targets and longer data collection, such as physical 
activity levels, gait speed, rate of falls, and a variety of periodic or continuously gathered 
measures of motor, cognitive, or other non-motor functions. In many cases, accuracy and 
reliability of these TOMs may not yet be sufficient to justify their deployment in Phase 
III clinical trials. 
 
Lack of compatibility among wearable systems. Most wearable systems developed to 
monitor individuals with PD are not compatible with one another. As a result, it may be 
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cumbersome or impossible to combine data gathered by TOMs developed by different 
manufacturers. This makes it difficult to guide behavioral changes or therapeutic 
interventions. Furthermore, devices developed by different manufacturers for the same 
purpose may not always yield the same result, raising questions about the validity of the 
mathematical algorithms that govern the data processing. Few currently available systems 
gather synchronized data from multiple body segments before transfer to a computer for 
whole-body analysis,
43
 in a way that is fully compatible with the simultaneous use of 
platforms developed by different manufacturers 
 
Limitations of available analytical methods. Despite our ability to collect and store 
extremely large datasets of TOMs, our ability to algorithmically analyze and synthetically 
display clinically and disease-relevant information to physicians and patients, remains 
limited. Here, clinical expertise is needed, for instance, to eliminate the “clinical noise” in 
the data analytical efforts. In addition, technical expertise is needed so that the field can 
take advantage of the tremendous advances that have been achieved over the past two 
decades in research areas such as signal processing and machine learning. Data analysis 
techniques that leverage advances in these research areas are important to achieving 
clinically meaningful TOMs. 
 
Practical limitations in user engagement. Software and hardware components of 
wearable systems are often not as user friendly or compelling to adopt as they should 
be.
44
 Currently, patient and caregiver engagement with wearable and mobile technology 
is modest, as shown by a recent study demonstrating that 32% of users stop using 
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wearables after 6 months, and 50% after just over a year.
45
  Similarly, there is a high 
dropout rate amongst smartphone apps users: 26% of apps are used only once and 74% of 
apps are not used more than 10 times.
45, 46
 Lack of motivation to use wearables/self-
monitoring systems should not be underestimated, particularly in the absence of 
meaningful feedback provided to their users. Preliminary evidence suggests that patient 
empowerment and their inclusion as active players in the development of research 
activities may favorably impact compliance.
47
 Research is needed to determine the 
characteristics of wearable systems for long-term monitoring of motor and non-motor 
symptoms that would be acceptable to patients. In particular, we need to ascertain the 
number of sensors needed to accurately monitor PD symptoms without negatively 
affecting compliance in a clinical context.  
 
OPPORTUNITIES 
Wearable systems provide the opportunity to measure and monitor the individual 
variability of motor and non-motor phenomena, minimize rater bias, and increase 
sensitivity to subclinical but possibly relevant physiologic changes (Table 2).
4, 10, 48, 49
  
 
Standard measurement platform. Several companies have tested or are in the process of 
assessing a variety of methods to probe individual motor and non-motor constructs. To 
avoid duplication of investments and efforts, an opportunity exists to identify the 
technologies and approaches with most versatility, greatest ease of deployment, least 
patient and physician encumbrance, and lowest cost. It should no longer be a question of 
whether a given motor phenomenon can be measured in yet a different manner (which it 
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can), but on how to choose a standard platform of TOMs behind which developers and 
end-users can coalesce. Efforts towards standardization – guided by the MDS Task Force 
on Technology but endorsed or sanctioned by regulatory agencies such as the Food and 
Drug Administration (FDA) and the European Medicines Agency (EMA) – will greatly 
facilitate technology adoption and the integration of different systems. 
 
Multi-domain measurements. With different types of disabilities comes the need for 
tailored measurement approaches to support the design of individualized interventions. 
Tremor measurement may be completely irrelevant to individuals with an akinetic or 
postural-instability gait-disorder (PIGD) phenotype of PD. Continuous step monitoring to 
capture freezing of gait episodes would be futile in patients without gait impairment. 
Systems that are designed for multi-domain data capture could provide researchers and 
clinicians with the flexibility of choosing the sensors to monitor individuals with different 
phenotypes of PD. In exploratory studies, an approach based on multi-domain data 
capture would increase the likelihood of finding relevant changes in one of the many 
“channels” of the system. This approach would also provide the opportunity for assessing 
correlated effects of symptoms of interest across other domains. 
 
Better phenotyping and subtyping. Tremor and tremorless (akinetic/PIGD) variants of 
PD are grossly defined clinical phenotypes, based on mainly observational evidence, with 
substantial heterogeneity.
50
 Besides these clinical phenotypes, there likely exist several 
disease subtypes defined by autonomic, cognitive or other domains of disability that 
could be captured by multichannel systems.
51
 In addition, it is conceivable that the 
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greater resolution of TOMS may detect novel phenomena that could serve to more 
sensitively stratify certain PD subtypes and serve as (or assist in the development of) 
biomarkers of disease progression. 
 
Precision medicine. By identifying areas of dysfunction and their relationship with 
therapy, TOMs can be used to provide customized feedback to individual patients and 
possibly stratify criteria that “predict” the responsiveness to distinct treatment paradigms, 
in a way that is similar to how consumer-based wearable devices already measure level of 
activity, sleep disturbances, etc. Smart algorithms could be developed to generate specific 
recommendations that would be made available directly to patients and clinicians to 
motivate changes in treatment and lifestyle-related behaviors, tailored to each person’s 
specific individual needs and disabilities. This approach would provide value for end-
users (both patients and their care team) and thereby improve adherence. 
 
Closed-loop (feedback) systems. Data collected using wearable sensors could be used to 
trigger device-based interventions. Much as ECG sensing is used in cardiac defibrillators 
to trigger the delivery of stimulation pulses, data collected from sensors positioned on the 
limbs and trunk could be used to predict, for instance, the onset of a freezing episode. 
The system may detect an increase in cadence with a corresponding decrease in step 
length or a change in frequency of the lower leg oscillations.
34
 The detection of such 
motor behaviors could trigger a device designed to deliver proprioceptive cues that could 
lead to a change in postural control and stepping pattern, that in turn could prevent a 
fall.
43, 52, 53
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Real-time symptom tracking. TOMs could offer real-time, continuously captured, rater-
independent data, in contrast with clinical assessments that rely upon subjective 
information gathered during sporadic, in-clinic evaluations.
54
 Continuous monitoring of 
parkinsonian symptoms could replace diary-based recordings of fluctuations and be used 
to track periods of OFF, OFF with dyskinesia (not currently captured using the Hauser 
diary), ON, and ON with dyskinesia over the time span of several days. 
 
The promise of remote monitoring. TOMs based on the use of wearable systems could 
improve healthcare delivery by providing assessment data when patients are not in the 
clinic. This possibility is particularly relevant for individuals with PD who live in areas 
with limited access to care. TOMs could provide ecologically valid data to help clinicians 
monitor responses to therapy and individualize management in order to optimize 
outcomes.
49
 Remote monitoring also offers the opportunity for healthcare cost reduction.
8
 
 
Better monitoring, better patient engagement, better outcomes. Innovation in sensor and 
communication technologies alongside mobile connectivity has enabled a process of 
“medical democratization”.1 The creation or support of TOMs for remote, continuous 
monitoring provides an opportunity for healthcare providers to scale and extend services 
offered to patients in order to better manage their health.
55
 TOMs can capture meaningful 
aspects of function that improve personalized patient care through an intuitive, 
interconnected, and energy-efficient interface.
56, 57
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POTENTIAL PITFALLS IN DEVELOPING TOMS 
Clinimetric validation pitfall. A number of studies have been focused on developing 
methods to derive TOMs that parallel the clinical assessment scales commonly utilized in 
clinic. These are important but potentially misguided efforts toward validating new 
TOMs at the clinic or home settings by attempting to force a simple quantitative 
agreement with widely used, previously validated subjective or semi-objective rating 
scales or questionnaires. However, it could be argued that, in theory, a “perfect” objective 
measurement should have a complicated quantitative match with an “imperfect” 
subjective one. This is because a clinical rater integrates many sources of information in 
order to produce a subjective score, including prior experience and expectations. So there 
is no a priori reason to believe that assessments performed by clinical raters would lead 
to a simple quantitative agreement with data features derived from sensor data. Indeed, 
the relationship between TOMs and subjective clinical scores may be highly complex and 
extremely difficult to ascertain in practice. 
 
To the extent that we are seeking more sensitive and “ecologically valid” technologies, 
TOMs may agree only loosely with clinical scales. An important aim of TOMs is to 
improve upon, rather than act as surrogates of, previously developed clinical scales. As 
these are developed, clinicians and regulatory agencies will need to consider that a new 
TOM which appears to provide clinically relevant measures of movement characteristics, 
but which does not correlate with the motor section of the Unified Parkinson Disease 
Rating Scale [UPDRS], for example, could be accepted as valid on the basis of its own 
merits if it can accurately represent patient-relevant endpoints. Engineers and clinicians 
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alike should be reminded to “think outside the box” and use the power of the technology 
to develop new scoring paradigms rather than solely generate sensor-based versions of 
existing clinical scores. 
 
Ecological validity pitfall. Efforts in ensuring validity, or the degree to which we are 
truly measuring what we intend to measure, increase in complexity with proliferating 
technologies, evolving in different platforms, and on different targets with unclear 
ecological and clinical relevance. To this end, before developing new TOMs, researchers 
would need to determine which constructs generated by routine clinical observations, and 
standardized by clinical scales and medical devices, are truly relevant to patients within 
such domains and are meaningful contributors to the performance of activities of daily 
living (ADLs). For example, if “dyskinesia” is not relevant as a construct to patients and 
is not a significant contributor to the performance of ADLs in their ecological 
environment, do we invest in maintaining its primacy in future technologies? Efforts to 
ensure system interoperability and to build open data repositories will help distinguishing 
relevant from futile TOMs. 
 
“Big data” pitfall. It has been demonstrated that an abundance of behavioral data can be 
captured from individuals and populations using largely unstructured, “crowd-sourced” 
efforts. These data may differentiate populations of loosely defined “Parkinson’s disease” 
(on the basis of generic measures of movement abnormalities) from “normal” subjects. 
However, although these measures can provide valuable background information at the 
population and community level, they cannot substitute for a careful neurological 
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examination, deep clinical phenotyping, and assessment via laboratory studies. At best, 
they complement but do not replace the phenomenological and pathophysiological 
granularity required for PD subtyping, much less predict the response of an individual to 
treatment. Ultimately, the reproducibility and responsiveness of individually selected 
TOMs confirmed beyond small pilot studies and accounting for contextual information 
and confounders, should prevail over simply obtaining a large body of population-level 
data. 
 
PREPARING FOR TOMS IN CLINICAL CARE AND THE RESEARCH SETTING 
Wearable systems that are used to gather TOMs in the home and community settings 
could generate real-time, accurate, sensitive, and rich datasets including contextual 
information and data such as the time of medication and food intake. While TOMs are 
typically derived from wearable sensors, contextual information is captured using 
companion applications (e.g., mobile apps and web-based applications). Wearable 
systems that are used to gather TOMs also provide an opportunity for multidirectional 
interactions among investigators/clinicians and patients/caregivers at a reasonable cost. In 
the clinical care setting, the use of wearable systems to generate TOMs could decrease 
the need for outpatient visits while maintaining high-quality care and high patient 
engagement. Likewise, the integration of TOMs with virtual-visit interfaces has the 
potential to greatly improve the accuracy and value of telemedicine visits. In the clinical 
research setting, the use of wearable systems could enhance protocol adherence and 
patient compliance, leading to fewer missing data points. Also, an appropriate choice of 
TOMs could lead to prospectively collecting data with high signal-to-noise ratio (with 
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regard to the effect size of interest) hence reducing the required sample size and the 
resulting study costs. The composite of TOMs, companion applications designed to 
gather contextual information and pharmacogenomics could enable precision medicine 
interventions.
58
 
 
Integrating technologies. The development of new TOMs is currently advancing in 
isolated silos rather than as part of concerted actions aimed to implement open platforms. 
The development of open platforms would be highly desirable in the context of obtaining 
comprehensive information on patients and populations of interest. An open platform 
may not yet be fostered by the brave new world of health-driven technologies. However, 
there are reasons for optimism. While in the traditional medical device market, short-term 
financial forces drive the creation of proprietary measuring instruments at the expense of 
multi-channel, interconnected systems, consumer-driven market forces are pushing 
heavily in the opposite direction, i.e. towards the development of open technology 
platforms. As consumer technologies evolve to achieve the clinimetric sophistication 
required for application in the clinical management of individuals with PD, the move 
towards shared, interoperable software and hardware for applications in research and 
clinical practice is also emerging. 
 
Smart delivery of treatment. Justification for the development and adoption of TOMs is 
strongest when presented in the context of improving the clinical management of 
individuals with PD. TOMs can be used as part of closed-loop systems designed to assist 
in the controlled delivery of medications. The development of such systems requires 
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manufacturing high-performance, energy-efficient and energy-harvesting sensors and 
storage modules.
59
 In this context, the development of nanomembranes and stretchable 
electronics on a polymeric substrate for intimate mechanical contact with soft tissue has 
been proposed.
60
 A critical unmet need is the ability to connect multi-sensor diagnostics 
to self-guided therapies in a closed-loop system. In the field of neuromodulation, deep 
brain stimulation (DBS) electrodes may also act as sensors, capable of recording local 
field potentials (for the presence or absence of beta-band oscillations) to automatically 
program the amplitude and frequency of stimulation, thus effectively closing the loop 
between measuring and treating.
61
 
 
Objective measures of specific movement impairments can also be used to tailor therapy. 
Proof of concept systems have been developed to predict the onset of pathological tremor 
using surface electromyographic (sEMG) and acceleration data, which could inform the 
design of the next generation of non-invasive closed-loop predictive ON-OFF controllers 
for DBS.
62, 63
 In the realm of physical rehabilitation, subtle asymmetries in gait, 
limitations in joint range of motion, or excessive postural sway indicating poor balance 
may be difficult to observe clinically but can be addressed by rehabilitation specialists 
when identified using TOMs. Through TOMs, therapists could personalize the therapy 
prescribed to each individual.
43
 A simple clinical measure such as the time needed to 
walk a specified distance does not provide the therapist with an understanding of the 
spatial and temporal gait performance or the musculoskeletal and dynamic balance 
characteristics that cause poor mobility. These factors could be captured using TOMs and 
hence guide the choice of appropriate therapeutic approaches. Longitudinal monitoring of 
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TOMs also has the potential for identifying small improvements or declines related to the 
intervention or the progression of the disease that could lead to changes in the prescribed 
rehabilitation intervention. 
 
Regulatory needs and commercialization. We anticipate that TOMs will eventually be 
routinely used in both clinical practice and research settings. Despite the promise of 
greater sensitivity and the presumed accuracy of collected data, regulatory validation of 
TOMs as efficacy and safety measures will require dedicated studies. The path to 
marketing for TOMs appears long and risky considering the short lifecycle of 
technological innovation and the costs associated with their development. Unlike drug 
development, where there is substantial precedent and a regimented path for marketing 
authorization, commercialization, and license protection, the path for TOMs and digital 
health solutions remains to be defined. It is critical that key stakeholders share the costs 
and financial rewards of technology development, implementation, and maintenance in 
order to accelerate and preserve innovation and growth. Despite opportunities to meet all 
stakeholder needs, the business model for development and deployment of TOMs in 
healthcare remains to be determined. Currently, healthcare payers show little incentive to 
financially reimburse TOMs, despite the promise for healthcare cost reduction, 
population management and delivery on high quality, efficient care. The lack of incentive 
may be driven by initial expenditures and the complexity of a rapidly evolving, but not 
yet fully integrated, technology market. Providers are also reluctant to fully adopt TOMs 
despite early evidence that they can improve patient outcomes and lead to overall 
improved care and patient satisfaction. Clinicians may not yet view TOMs as an 
 29 
opportunity to support clinical decision-making and increase productivity. Patients are 
also reluctant to pay out of pocket despite opportunities for improved access to better care 
and better outcomes. Building a solid ‘business case’ – including properly designed cost-
effectiveness studies – is much needed. A value-based care approach could be an 
attractive solution, where deployment of TOMs is funded as part of an integrated care 
solution where providers are rewarded for good outcomes per invested dollar, and where 
the decision to engage TOMs is left to the providers and patients. Finally, in addition to 
funding agencies, regulatory bodies such as the FDA and the EMA should increase 
efforts toward establishing programs that encourage the adoption of standards aimed to 
assure interoperability of wearable systems and the development of open data 
repositories. 
 
Integration into medical care and reimbursement. Payers do not yet provide 
reimbursement for medical services provided by TOMs and companion apps. This limits 
the rate of innovation and the opportunities for integration of TOMs into medical care. 
Establishing reimbursement mechanisms will require demonstration that, along with the 
enhancements in diagnostics and therapeutics, TOMs can be integrated in quality control 
concepts, help reduce costs, and improve patients’ quality of life while guarding against 
privacy concerns. Quantifying clinical benefits of interventions using TOMs is 
anticipated to become increasingly important in healthcare as the allocation of resources 
is expected to be tied to objective outcome measures.  
 
CONCLUSIONS AND NEXT STEPS 
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Despite challenges, the continuous improvements in technological sophistication, 
versatility, and wearability of sensors have created opportunities to collect disease-
relevant data using targets consequential to patients and sensitive to PD-specific 
symptoms and milestones. In order to translate these opportunities into enhanced care, 
better self-management options for PD patients, and overall improved health care 
outcomes, technologies will need to be 1)  developed as open platforms and integrated 
with electronic medical record systems, 2)  suitable for the acquisition of data that 
captures motor and non-motor phenomena, and 3)  integrated in treatment delivery 
systems. The International Parkinson and Movement Disorders Society Task Force on 
Technology aims at reversing the current model of simply adapting available 
technologies to meet patient management and research endpoints. As such, the Task 
Force will assist in improving the academic and regulatory environments for technology 
developers by encouraging the sanctioning of open standard platforms for technology-
based measurements and treatments by, e.g., the FDA and EMA. This collaborative 
endeavor will materialize in the development of integrated, multi-channel, and in many 
instances closed-loop feedback systems that can achieve more sophisticated clinico-
pathophysiologic characterization, better informed tailoring of symptomatic therapy, 
greater patient engagement and self-assessment, and better subgroup targeting of patients 
for testing of future disease-modifying treatments. 
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Figure Legend 
 
Figure 1.  Schematic representation of a subject undergoing monitoring in the home 
setting using wearable and ambient sensors. The technology shown includes a wireless 
unit strapped around the wrist, band-aid like sensors attached to the lower limbs, a 
wearable camera worn as a pendant, a smart watch, and a mobile phone clipped on the 
belt used as gateway to relay the data to the cloud to assess specific functions (using its 
embedded sensors) as well as to communicate with the subject (using customized apps). 
Ambient sensors and computer technologies are utilized in the home settings to gather 
additional information or replace wearable sensors when wearable sensors cannot be 
used. The integration of wearable technology with smart devices enables remote 
monitoring of patients with PD and real-time feedback to clinicians, family/caregivers, 
and the patients themselves. 
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